Showing results (191-200 of 319) with videos related to
Sort By:
Pageof 32
Journal of Acquired Immune Deficiency Syndromes (1999)|July 27, 2001
Genotypic correlates of a virologic response to stavudine after zidovudine monotherapyN S Shulman, R A Machekano, R W Shafer, et al.Antimicrobial Agents and Chemotherapy|March 19, 2002
Evolution of primary protease inhibitor resistance mutations during protease inhibitor salvage therapyRami Kantor, W Jeffrey Fessel, Andrew R Zolopa, et al.Antiviral Therapy|May 17, 2007
Improved prediction of response to antiretroviral combination therapy using the genetic barrier to drug resistanceAndre Altmann, Niko Beerenwinkel, Tobias Sing, et al.AIDS (London, England)|June 21, 2001
Phenotypic hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in treatment-experienced HIV-infected patients: impact on virological response to efavirenz-based therapyN Shulman, A R Zolopa, D Passaro, et al.Journal of Clinical Microbiology|April 3, 2001
High degree of interlaboratory reproducibility of human immunodeficiency virus type 1 protease and reverse transcriptase sequencing of plasma samples from heavily treated patientsR W Shafer, K Hertogs, A R Zolopa, et al.Journal of Neurovirology|February 21, 2014
Genome-wide association study of peripheral neuropathy with D-drug-containing regimens in AIDS Clinical Trials Group protocol 384Paul D Leger, Daniel H Johnson, Gregory K Robbins, et al.Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 19, 2025
Design and evaluation of next-generation HIV genotyping for detection of resistance mutations to 28 antiretroviral drugs across five major classes including lenacapavirSung Yong Park, Christian Takayama, Jenica Ryu, et al.AIDS Research and Human Retroviruses|January 11, 2007
N88D facilitates the co-occurrence of D30N and L90M and the development of multidrug resistance in HIV type 1 protease following nelfinavir treatment failureYumi Mitsuya, Mark A Winters, W Jeffrey Fessel, et al.Antimicrobial Agents and Chemotherapy|February 19, 2000
Delavirdine susceptibilities and associated reverse transcriptase mutations in human immunodeficiency virus type 1 isolates from patients in a phase I/II trial of delavirdine monotherapy (ACTG 260)L M Demeter, R W Shafer, P M Meehan, et al.Scientific Reports|November 5, 2015
Self-regulated oscillation of transport and topology of magnetic islands in toroidal plasmasK Ida, T Kobayashi, T E Evans, et al.Pageof 32